C. elegans ND Models (CRCHUM – Universite de Montreal)

https://www.neurodegenerationresearch.eu/survey/c-elegans-nd-models-crchum-universite-de-montreal/

Name of Resource

C. elegans ND Models (CRCHUM - Universite de Montreal)

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Alex

Name of Principal Investigator - Last name

Parker

Address of institution -Institution

CRCHUM - Universite de Montreal

Address of institution - Street address
Address of institution - City

Montreal

Address of institution - Postcode
Country

Canada

Website

https://sites.google.com/site/jalexparker/welcome

Contact email

Summary

C. elegans models of neurodegeneration

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions? (1)

Motor neurone diseases| Alzheimer's disease and other dementias| Neurodegenerative disease in general

Q1b. Does your resource hold

Animals| Genetic Material (e.g. DNA, RNA, vectors)

Q2a. Does the resource act as a centre for access and distribution to external groups (who are not the Principal Investigators (PI) for the resource)?

Yes

Q2b. If Yes, what procedures and rules apply for access?

Apply to PI or co-ordinator at resource| Access independent of collaboration with PI

Q3a. Does your resource develop experimental models (animal/cell) for external groups?

Yes

Q3b. If YES and your resource is related to an ANIMAL model, what types of models are provided?

Wild type| Genetically Modified| Humanised

Q3c. If YES and your resource is related to a CELL model, what types of models are provided?
Q4a. Is this activity supported as:
Q4b. Do you deposit what you supply in any kind of central repository?
Disease

ALS| HD| PD

Species

C.elegans| C.elegans| C.elegans

Available to external user

Yes| No| No

Full phenotypic character

Yes| Yes| Yes

Please indicate the phenotypes

Motor neuron degeneration| Neuronal dysfunction| Dopaminergic neuron degeneration

List of genotypes or other subtypes

Q5b. Cognitive function, No of models
Q5b. Cognitive function, Available to external users
Q5b. Cognitive function, Full phenotypic characterisation
Q5b. Cognitive function, Nature of phenotype
Q5b. Motor function, No of models

5

Q5b. Motor function, Available to external users

Yes

Q5b. Motor function, Full phenotypic characterisation

Yes

Q5b. Motor function, Nature of phenotype

Degenerating motor neurons

Q5b. Physiological function, no of models
Q5b. Physiological function, Available to external users
Q5b. Physiological function, Full phenotypic characterisation
Q5b. Physiological function, Nature of phenotype
Q5b. Other function (please specify), no of models
Please specify other function
Q5b. Other function (please specify), Available to external users
Q5b. Other function (please specify), Full phenotypic characterisation
Q5b. Other function (please specify), Nature of phenotype
Q6. Please indicate if your resource is already linked into European or international consortia or networks?
Q7a. Is maintenance of this resource dependent on continued funding?

No

Q7b. If yes, when does the current funding period end?
Q7c. What is the expected lifespan of the resource (in years)?

Indefinite, can be frozen

Q7d. Are there other plans affecting future use that it may be useful to know?

Types:
Experimental Models

Member States:
Canada

Diseases:
N/A

Years:

2016

Database Categories:
N/A

Database Tags:
N/A